# GLP-1s, Pneumonia and Sepsis: A Better-Built Cohort

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/glp1-pneumonia-and-sepsis-risk

> Among 331,863 matched adults with type 2 diabetes, GLP-1 users had 40% less new pneumonia over a year than DPP-4 inhibitor users. The design is about as good as observational research gets, which is the point.

## Key points

- Pneumonia HR 0.60 and severe sepsis HR 0.61 vs DPP-4 inhibitors, in 331,863 matched patients.
- Active comparator + new user + 1:1 matching: roughly the best an observational study can be built.
- The comparator is another drug, not nothing, and these are relative figures on uncommon events.
- SGLT2 inhibitors showed the same direction at 0.75 for both outcomes.

Among 331,863 matched adults with type 2 diabetes, those starting a GLP-1 drug had a **40% lower** rate of new pneumonia and a similar reduction in severe sepsis over a year, compared with those starting a DPP-4 inhibitor.[1] That is a large effect from observational data, but the way this study was built makes it harder to dismiss than most.

## What was found

Using a global federated database of electronic medical records, researchers compared adults with type 2 diabetes newly prescribed one drug class against those newly prescribed DPP-4 inhibitors, matched one to one on measured characteristics and followed for twelve months.[1]

*Incident pneumonia and severe sepsis against DPP-4 inhibitors, after 1:1 propensity score matching. Twelve months of follow-up.*

| Comparison | Patients | Pneumonia | Severe sepsis |
| --- | --- | --- | --- |
| GLP-1 receptor agonists vs DPP-4i | 331,863 | HR 0.60 (0.58–0.62) | HR 0.61 (0.59–0.63) |
| SGLT2 inhibitors vs DPP-4i | 352,687 | HR 0.75 (0.73–0.78) | HR 0.75 (0.73–0.77) |

Both newer classes came out ahead of the older one, on both outcomes, with narrow confidence intervals. The consistency across two different drug classes and two different infections is part of what makes the pattern interesting.

## Why this design deserves more trust than most

A comparison group can manufacture a result. In [the cancer cohorts](https://glpwatchdog.org/research/glp1-and-cancer-risk-what-the-cohorts-show), one study reported 91% lower mortality against insulin users and nothing at all against a modern comparator. This study is built to avoid exactly that.

- **Active comparator.** The comparison is another diabetes drug, not no treatment. Both groups have diabetes and both are being actively managed, which removes a great deal of the difference that sinks weaker studies.
- **New user design.** Everyone is starting their drug, so the comparison is not between new patients and people who have already tolerated a drug for years.
- **Propensity score matching, one to one**, on measured characteristics.
- **Very large samples**, which is why the confidence intervals are as tight as they are.

> **This is roughly the best an observational study can be built.** It still cannot rule out that clinicians choose newer, more expensive drugs for patients who are healthier in ways records do not capture (frailty, functional status, whether someone attends appointments). Those unmeasured differences are exactly what would produce a lower infection rate.

## What the number does not say

A 40% reduction sounds like a reason to take the drug for infection protection. It is not, for three separate reasons.

1. **The comparator is another drug, not nothing.** This says GLP-1 users had fewer infections than DPP-4 inhibitor users. It does not establish what would happen against no treatment at all.
2. **These are relative figures.** Pneumonia and severe sepsis are uncommon over twelve months in this population, so a 40% relative reduction is a small absolute one.
3. **Twelve months is short** for an outcome shaped by long-term glycemic control and body weight, both of which move slowly.

The authors’ own conclusion is that further research and focused randomized trials are warranted, which is the right place to leave it.[1]

## Is there a plausible mechanism?

Several, none proven. Better glycemic control reduces infection risk in diabetes and is well established. Obesity impairs respiratory mechanics and immune function, and these drugs reduce it. GLP-1 receptors appear in lung tissue and there is preclinical work on anti-inflammatory effects. A protective association has also been reported for asthma, in [a Taiwanese cohort of people with type 2 diabetes](https://glpwatchdog.org/research/glp1-and-asthma-risk), though it faded as the asthma grew more severe.

Plausibility counts for something, but it is also what makes this kind of result risky. A finding with an obvious mechanism is easier to believe than one without, so it needs the same scrutiny, not less.

## Frequently asked questions

### Do GLP-1 drugs reduce pneumonia risk?

In a study of 331,863 matched adults with type 2 diabetes, those starting a GLP-1 had a 40% lower rate of new pneumonia over twelve months than those starting a DPP-4 inhibitor, with a similar reduction in severe sepsis. It is observational, and the authors call for randomized trials.

### Is this a reason to take a GLP-1?

No. No GLP-1 is approved for infection prevention, the comparison was against another diabetes drug rather than no treatment, and pneumonia and sepsis are uncommon over a year, so a 40% relative reduction is a small absolute difference.

### Why should I trust this more than other cohort studies?

Because of how it was built: an active comparator, a new-user design, one-to-one propensity matching and very large samples. That combination removes much of the bias that ruins weaker observational work. It cannot remove unmeasured differences in how sick patients are.

### Did other diabetes drugs show the same thing?

SGLT2 inhibitors did, at a smaller magnitude, with hazard ratios of 0.75 for both pneumonia and severe sepsis against DPP-4 inhibitors. Both newer classes came out ahead of the older one on both outcomes.

### How might a diabetes drug affect infection risk?

Several plausible routes: better glycemic control lowers infection risk in diabetes, obesity impairs respiratory mechanics and immune function, and GLP-1 receptors are present in lung tissue. None of these is established as the explanation, and a plausible mechanism makes a finding easier to believe rather than more likely to be true.

## References

1. Henney AE, Riley DR, Hydes TJ, et al. Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data. Thorax. 2024. PMID: 39645259. https://pubmed.ncbi.nlm.nih.gov/39645259/

---

Cite as: GLP Watchdog, Nora Bissett, "GLP-1s, Pneumonia and Sepsis: A Better-Built Cohort", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/glp1-pneumonia-and-sepsis-risk

Canonical HTML page: https://glpwatchdog.org/research/glp1-pneumonia-and-sepsis-risk

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
